Developing Potential Treatments for a Variety of Tumor Types

Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotype through innate and adaptive immune responses. Our clinical development plan is based on these two components of the mechanism of action, with a focus on obtaining regulatory approval as soon as possible.

  • Defined registration pathway in metastatic breast cancer (mBC) allowing for rapid initiation of a single phase 3 trial required for approval
  • Leverage innate and adaptive immune mechanisms of pelareorep in studies with checkpoint inhibitors as well as targeted and immunomodulatory (IMiD) combinations to explore new treatment applications

Partnering, Collaborating & Combining Towards the Future

Oncolytics will grow through partnerships, collaborations and combinations. We have a Master Supply Agreement with Roche to supply Tecentriq® for Oncolytics’ clinical development program, which was put to use immediately in a collaboration with SOLTI – a breast cancer window-of-opportunity study of pelareorep combined with the anti-PD-L1 checkpoint inhibitor. We also have a collaboration with Myeloma UK and Celgene in a relapsing myeloma study of pelareorep combined with Imnovid®/Revlimid®. Additionally, we have combination studies with Merck’s anti-PD-1 checkpoint inhibitor Keytruda®, in both multiple myeloma and pancreatic cancer and one with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor Opdivo® in multiple myeloma.

We have a partnership with Adlai Nortye in China to develop pelareorep for metastatic breast cancer, as well as additional indications, and continue to investigate further collaboration and partnership opportunities, particularly with checkpoint inhibitors and immunomodulatory drugs that will help us to advance pelareorep in the adjuvant setting.


Pelareorep is currently being manufactured at commercial scale in its final formulation under a commercial supply agreement with MilliporeSigma.